Clinical Trials
137 trialsSurgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
NRG Oncology
CISTO
University of Washington
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
M.D. Anderson Cancer Center
Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer
University of Washington
P3BC
Icahn School of Medicine at Mount Sinai
Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy
UNC Lineberger Comprehensive Cancer Center
Recovery Support for Bladder Cancer Patients and Caregivers
Northwell Health
Bristol Bladder Trial
University Hospitals Bristol and Weston NHS Foundation Trust
18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy
Brigham and Women's Hospital
HYBRID
Institute of Cancer Research, United Kingdom
PERTINENCE
Institut Cancerologie de l'Ouest
GEMDOCE
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate
Jonsson Comprehensive Cancer Center
Avelumab and Radiation in Muscle-Invasive Bladder Cancer
Dana-Farber Cancer Institute
Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer
UNC Lineberger Comprehensive Cancer Center
GETUGV04
Institut du Cancer de Montpellier - Val d'Aurelle
Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder
University of Southern California
TEP-Vessie
Institut Bergonié
Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer
University of Washington
Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)
Memorial Sloan Kettering Cancer Center
Afatinib in Advanced Refractory Urothelial Cancer
University of Chicago
Intravenous (IV) Vitamin C With Chemotherapy for Cisplatin Ineligible Bladder Cancer Patients
University of Kansas Medical Center
Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects
Hoosier Cancer Research Network
Intravesicular Abraxane for Treatment-Refractory Bladder Cancer
Columbia University
Study of Genistein in Reducing Side Effects of Superficial Bladder Cancer Treatment
Emory University
PRISMS
UNC Lineberger Comprehensive Cancer Center
PCR-MIB
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
Stanford University
FITBIT
University of Pennsylvania
PemCab
University of Utah
Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma
Indiana University
PrE0807
PrECOG, LLC.
MARC
Southern Illinois University
Behavioral Dietary Intervention for the Improvement of Bladder Cancer Survivorship
Roswell Park Cancer Institute
Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing
Hoosier Cancer Research Network
Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer
Northwestern University
Pembrolizumab in Treating Patients With Bladder Cancer Undergoing Radical Cystectomy
M.D. Anderson Cancer Center
Radiogenomics of Muscle Invasive Bladder Cancer
Cedars-Sinai Medical Center
AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer
The University of Texas Health Science Center at San Antonio
OU-SCC-ABC
University of Oklahoma
CIRTiN-BC
University of Texas Southwestern Medical Center
Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer
Fred Hutchinson Cancer Center
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
Rutgers, The State University of New Jersey
Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma
SCRI Development Innovations, LLC
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Hoosier Cancer Research Network
Evaluation of Oxaliplatin and Gemcitabine in Patients With Metastatic Bladder Cancer
University of California, Irvine
Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study
M.D. Anderson Cancer Center
Neutrophil-to-Lymphocyte Ratio in Bladder Cancer: A Secondary Biomarker Analysis of SWOG 8710
Abramson Cancer Center at Penn Medicine
BIC
Corewell Health West
Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer
Memorial Sloan Kettering Cancer Center